In Vitro/In Vivo Evaluation of Radiolabeled [99mTc(CO)3]+-Hydroxyurea and Fluorescein Isothiocyanate-Hydroxyurea
Küçük Resim Yok
Tarih
2016
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Mary Ann Liebert Inc.
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
The aim of current study is to examine hydroxyurea (HU), which is an antineoplastic drug used for the treatment of leukemia, sickle-cell disease, HIV, psoriasis, thrombocythemia, and various neoplastic diseases in two aspects. The active ingredient hydroxyurea was obtained by purification of the capsule form drug, commercially named as HYDREA. Then, [99mTc(CO)3]+core radiolabeling with HU was performed as first aspect. Quality control studies of 99mTc(CO)3-HU complex were performed by thin-layer radiochromatography and high-performance liquid radiochromatography methods. The results demonstrated that the radiolabeling yield was quite high (98.43% ± 2.29%). Also, 99mTc(CO)3-HU complex has good stability during the 24-hour period. Biological behavior of 99mTc(CO)3-HU complex is evaluated by biodistribution studies on Wistar Albino rats. Fluorescein isothiocyanate (FITC) labeling of HU was performed as second aspect. Fluorometric evaluation of binding efficacy and fluorescence imaging studies on MCF7 and Hela cell lines were carried out. It was thought that the knowledge achieved in this study would contribute to using 99mTc(CO)3-HU complex as an imaging agent, which inhibits the DNA synthesis selectively, by inhibiting ribonucleotide reductase enzyme. It was observed that FITC-HU has noteworthy incorporation on both cell lines. © Copyright 2016, Mary Ann Liebert, Inc. 2016.
Açıklama
Anahtar Kelimeler
antineoplastic, fluorescence imaging, hydroxyurea, in vitro/in vivo, [99mTc(CO)3]+ core
Kaynak
Cancer Biotherapy and Radiopharmaceuticals
WoS Q Değeri
Scopus Q Değeri
Q2
Cilt
31
Sayı
1
